We anticipate that the RNA mutation-based A3A assay will significantly advance our understanding of the function of A3A in tumorigenesis and allow us to exploit A3A-induced vulnerabilities in cancer therapy more effectively. This evidence concerns the gene APOBEC3A and cancer.